Ophthalmology

Two-year XTEND trial data shows proactive aflibercept led to meaningful functional and anatomic improvements that were maintained across the study period.

Patients with lung cancer treated with EGFR inhibitors may experience a greater risk for keratitis, particularly with afatinib treatment.

A meta-analysis of RCTs revealed significant advantages with faricimab treatment in improving CST and reducing injection frequency among eyes with AMD or DME.

Positive interim data from the TEASE-3 clinical trial show gildeuretinol slows the progression of Stargardt Disease for up to six years.

Results of the 76-week trial suggest that a treat-and-extend aflibercept regimen yields similar functional and anatomic outcomes as fixed dosing every 8 weeks among patients with nAMD.

Eyes with DED showed a correlation between the severity of ocular symptoms, obtained using dry eye and pain questionnaires, and all aspects of sleep quality.

A new cohort study in China reports suggests the structure of green space decreased the relative risk of myopia among school-aged children.

A retrospective cohort study showed patients with Alzheimer disease treated with AChEIs had a slightly lower risk of incident AMD compared with untreated patients.

A case-control analysis shows the majority of autoimmune diseases demonstrate no effect on the development of new-onset age-related macular degeneration.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our December 2023 month-in-review features a recap of This Year in Medicine, the latest updates to the ophthalmic pipeline, and the newest episode of our KOL-led podcast series.

Over 8 years of follow-up, patients with high myopia and a rapid progression trajectory had a nearly 7 times higher risk of developing pathological macular degeneration.

Among more than 3 million adults, a team of investigators observed an increased risk of both falls and fractures among people with cataract, age-related macular degeneration, and glaucoma.

A systematic review and meta-analysis suggests the dual pathway-targeting faricimab provides some greater benefit in outcomes like CST at fewer injections and without compromise of safety to anti-VEGF monotherapies.

Firework-related eye injuries were more likely in areas where fireworks were legal, compared to banned areas.

Reports of eye infection and enucleation related to OTC eye drops concerned the eye care community in 2023 and drove increased vigilance towards ensuring safer ophthalmic products.

A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents.

Cross-sectional data show an increasing incidence of syphilitic uveitis–related hospitalizations in the US between 2010 and 2019.

Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.

Increases in the working-age population during the 30-year period may have contributed to the global burden of visual impairment

These new findings represent the only PTC case to look at such a unique number of concurrent comorbidities in current medical literature.

These phase 2 data indicate that the implant may be a helpful addition to clinicians’ interventional glaucoma armamentarium for patients.

Significant increases in macular and choroidal thickness were observed in the fovea and perifovea at all postoperative visits in patients with diabetic retinopathy.

Results from a systematic review highlighted the clinical need for specific biomarkers for PAD and the viability of noninvasive ophthalmic imaging techniques for diagnosis.

A substudy of the ASCEND trial offers insight into the effects of omega-3 fatty acids use on risk of diabetic retinopathy in people with diabetes.

In a new study, inserting the XEN-45 implant in patients with uncontrolled uveititc glaucoma prevented conventional glaucoma surgery in 83.3% of patients.